Laboratorios Farmaceúticos Rovi SA (LABFF)
67.17
0.00 (0.00%)
USD |
OTCM |
Sep 17, 16:00
Laboratorios Farmaceúticos Rovi Enterprise Value : 3.431B for Sept. 17, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 17, 2026 | 3.431B |
| September 16, 2026 | 3.431B |
| September 15, 2026 | 3.431B |
| September 14, 2026 | 3.431B |
| September 11, 2026 | 3.431B |
| September 10, 2026 | 3.431B |
| September 09, 2026 | 3.431B |
| September 08, 2026 | 3.431B |
| September 04, 2026 | 3.431B |
| September 03, 2026 | 3.431B |
| September 02, 2026 | 3.431B |
| September 01, 2026 | 3.431B |
| August 31, 2026 | 3.431B |
| August 28, 2026 | 3.431B |
| August 27, 2026 | 3.431B |
| August 26, 2026 | 3.431B |
| August 25, 2026 | 3.431B |
| August 24, 2026 | 3.431B |
| August 21, 2026 | 3.431B |
| August 20, 2026 | 3.431B |
| August 19, 2026 | 3.431B |
| August 18, 2026 | 3.431B |
| August 17, 2026 | 3.431B |
| August 14, 2026 | 3.431B |
| August 13, 2026 | 3.431B |
| Date | Value |
|---|---|
| August 12, 2026 | 3.431B |
| August 11, 2026 | 3.431B |
| August 10, 2026 | 3.431B |
| August 07, 2026 | 3.431B |
| August 06, 2026 | 3.431B |
| August 05, 2026 | 3.431B |
| August 04, 2026 | 3.431B |
| August 03, 2026 | 3.431B |
| July 31, 2026 | 3.364B |
| July 30, 2026 | 3.364B |
| July 29, 2026 | 3.364B |
| July 28, 2026 | 3.364B |
| July 27, 2026 | 3.364B |
| July 24, 2026 | 3.364B |
| July 23, 2026 | 3.364B |
| July 22, 2026 | 3.364B |
| July 21, 2026 | 3.364B |
| July 20, 2026 | 3.364B |
| July 17, 2026 | 3.364B |
| July 16, 2026 | 3.364B |
| July 15, 2026 | 3.364B |
| July 14, 2026 | 3.364B |
| July 13, 2026 | 4.630B |
| July 10, 2026 | 3.364B |
| July 09, 2026 | 3.364B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Almirall SA | 2.914B |
| AstraZeneca PLC | 541.60B |
| ANI Pharmaceuticals, Inc. | 1.967B |
| Corcept Therapeutics, Inc. | 12.10B |
| Veru, Inc. | 17.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 87.12M |
| Revenue (Quarterly) | 222.85M |
| Total Expenses (Quarterly) | 135.65M |
| EPS Diluted (Quarterly) | 1.705 |
| Gross Profit Margin (Quarterly) | 63.56% |
| Profit Margin (Quarterly) | 39.09% |
| Earnings Yield | 6.28% |
| Operating Earnings Yield | 5.12% |
| Normalized Earnings Yield | 6.278 |